2008
- 2008/12/01
- Supply of RetroNectin® to UCLA for TCR-gene therapy clinical trials of advanced melanoma
- 2008/10/07
- Start of the HSV-TK Gene Therapy Clinical Trial for Relapsed Leukemia
- 2008/09/29
- Takara Bio Inc. to supply RetroNectin® to University of Washington School of Medicine for gene therapy targeting glioblastoma, a type of malignant brain tumors
- 2008/09/10
- Takara Bio Grants Promega Corporation a license for LA-PCR Technology
- 2008/09/01
- Takara Bio to collaborate with Sun Yat-Sen University in China to conduct clinical research of cancer immunotherapy targeting hepatocellular carcinoma using RetroNectin® expansion culture system
- 2008/06/03
- Takara Bio has established an endowed chair in Kyoto Prefectural University of Medicine for clinical development on cutting edge cancer immunotherapy
- 2008/05/13
- Announcement of Takara Bio's mid-term management plan
- 2008/04/30
- Start of clinical research of cancer immunotherapy using RetroNectin® expansion culture system at Tianjin Cancer Institute & Hospital, China
- 2008/01/30
- 3rd factory building of Takara Biotechnology (Dalian) Co., Ltd. which is our manufacturing center of research reagents in China has established
- 2008/01/22
- MolMed S.p.A., a strategic partner of Takara Bio in gene therapy, obtains a regulatory approval to start a Phase III trial of HSV-TK gene therapy for high risk acute leukemia in Italy
- 2008/01/09
- Takara Bio to enter into an M-CRADA with Dr. Rosenberg's group at NCI initiating pre-clinical studies of gene therapy using RetroNectin®-expansion culture system
